Cancer immunoediting: from immunosurveillance to tumor escape

The concept that the immune system can recognize and destroy nascent transformed cells was originally embodied in the cancer immunosurveillance hypothesis of Burnet and Thomas. This hypothesis was abandoned shortly afterwards because of the absence of strong experimental evidence supporting the concept. New data, however, clearly show the existence of cancer immunosurveillance and also indicate that it may function as a component of a more general process of cancer immunoediting. This process is responsible for both eliminating tumors and sculpting the immunogenic phenotypes of tumors that eventually form in immunocompetent hosts. In this review, we will summarize the historical and experimental basis of cancer immunoediting and discuss its dual roles in promoting host protection against cancer and facilitating tumor escape from immune destruction.

[1]  M. Burnet Cancer—A Biological Approach , 1957, British medical journal.

[2]  M BURNET,et al.  Cancer—A Biological Approach* , 1957, British medical journal.

[3]  T. Nash Chemical Carcinogenesis , 1957, Nature.

[4]  M. Burnet IMMUNOLOGICAL FACTORS IN THE PROCESS OF CARCINOGENESIS. , 1964, British medical bulletin.

[5]  L. Old,et al.  IMMUNOLOGY OF EXPERIMENTAL TUMORS. , 1964, Annual review of medicine.

[6]  Old Lj,et al.  Immunology of Experimental Tumors , 1964 .

[7]  J. Miller,et al.  Effect of Neonatal Thymectomy on the Induction of Sarcomata in C57BL Mice , 1965, Nature.

[8]  Y. Nishizuka,et al.  Enhancing Effect of Thymectomy on Hepatotumorigenesis in Swiss Mice following Neonatal Injection of 20-Methylcholanthrene , 1965, Nature.

[9]  S. Flanagan,et al.  'Nude', a new hairless gene with pleiotropic effects in the mouse. , 1966, Genetical research.

[10]  N. Trainin,et al.  Enhancement of lung adenoma formation by neonatal thymectomy in mice treated with 7,12‐dimethylbenz(a)anthracene or urethan , 1967, International journal of cancer.

[11]  E. M. Pantelouris,et al.  Absence of Thymus in a Mouse Mutant , 1968, Nature.

[12]  B. C. F. F. Israel Penn M.B. Malignant Tumors in Organ Transplant Recipients , 1970, Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer.

[13]  F. Burnet The concept of immunological surveillance. , 1970, Progress in experimental tumor research.

[14]  H. Kaplan Role of Immunologic Disturbance in Human Oncogenesis: Some Facts and Fancies , 1971, British Journal of Cancer.

[15]  R. Prehn Perspectives on oncogenesis: does immunity stimulate or inhibit neoplasia? , 1971, Journal of the Reticuloendothelial Society.

[16]  R. Gatti,et al.  Occurrence of malignancy in immunodeficiency diseases: A literature review , 1971, Cancer.

[17]  N. Burstein,et al.  Neonatal Thymectomy and Non-viral Mammary Tumours in Mice , 1971, Nature.

[18]  J. Daly,et al.  Long-term spontaneous tumor incidence in neonatally thymectomized mice. , 1973, Journal of immunology.

[19]  G. Klein Immunological surveillance against neoplasia. , 1973, Harvey lectures.

[20]  O. Stutman Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice , 1974, Science.

[21]  J. Rygaard,et al.  Is immunological surveillance not a cell-mediated immune function? , 1974, Transplantation.

[22]  J. Rygaard,et al.  The mouse mutant nude does not develop spontaneous tumours. An argument against immunological surveillance. , 2009, Acta pathologica et microbiologica Scandinavica. Section B: Microbiology and immunology.

[23]  R. Custer,et al.  Spontaneous and induced tumor incidence in germfree "nude" mice. , 1975, Journal of the Reticuloendothelial Society.

[24]  O. Stutman Immunodepression and malignancy. , 1975, Advances in cancer research.

[25]  L. Fatti,et al.  Prostatic carcinoma. Some morphological features affecting prognosis , 1976, Cancer.

[26]  N. Di Lorenzo,et al.  Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases. , 1978, Journal of neurosurgery.

[27]  R. Herberman,et al.  Natural cell-mediated immunity. , 1978, Advances in cancer research.

[28]  B. Giovanella,et al.  The Nude Mouse in Experimental and Clinical Research , 1978 .

[29]  O. Stutman Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. , 1979, Journal of the National Cancer Institute.

[30]  C. Uyttenhove,et al.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice , 1980, The Journal of experimental medicine.

[31]  Tumor antigens. , 1981, The New England journal of medicine.

[32]  P. Davaris,et al.  Prognostic significance of histologic host response in cancer of the large bowel , 1981, Cancer.

[33]  C. Cohen,et al.  Histologic correlates of virulence in ovarian adenocarcinoma. II. Morphologic correlates of host response. , 1982, American journal of obstetrics and gynecology.

[34]  M. Kripke,et al.  Immunoselection of tumor cell variants by mice suppressed with ultraviolet radiation , 1982, The Journal of experimental medicine.

[35]  L. Thomas On immunosurveillance in human cancer. , 1982, The Yale journal of biology and medicine.

[36]  C. Cohen,et al.  Histologic correlates of virulence in ovarian adenocarcinoma , 1982 .

[37]  T. Hunig T-cell function and specificity in athymic mice. , 1983, Immunology today.

[38]  S. Ikehara,et al.  Functional T cells in athymic nude mice. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[39]  I. Weiler,et al.  Rearrangement of antigen receptor genes is defective in mice with severe combined immune deficiency , 1986, Cell.

[40]  J. Jass Lymphocytic infiltration and survival in rectal cancer. , 1986, Journal of clinical pathology.

[41]  J. Ravetch,et al.  Biochemical characterization of a gamma interferon-inducible cytokine (IP-10) , 1987, The Journal of experimental medicine.

[42]  L. Sherman,et al.  The composition of the T cell receptor repertoire in nude mice. , 1987, Journal of immunology.

[43]  R. Herberman,et al.  Lymphocyte-mediated cytotoxicity. , 1987, Pediatric annals.

[44]  A. Macleod,et al.  Cancer after transplantation. , 1988, BMJ.

[45]  A. Halpern,et al.  Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.

[46]  S. Ménard,et al.  Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factors , 1991, International journal of cancer.

[47]  E. Unanue,et al.  Natural Immunity: A T‐Cell‐Independent Pathway of Macrophage Activation, Defined in the scid Mouse , 1991, Immunological reviews.

[48]  V. Stewart,et al.  RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement , 1992, Cell.

[49]  K. Jauhiainen,et al.  Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. , 1992, European journal of cancer.

[50]  P. Leder,et al.  IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo , 1993, The Journal of experimental medicine.

[51]  McGuire Wl,et al.  Tumour Infiltrating Lymphocytes as an Independent Prognostic Factor in Transitional Cell Bladder Cancer , 1993 .

[52]  P. Matzinger Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[53]  R. Schreiber,et al.  Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. , 1994, Immunity.

[54]  L. Koniaris,et al.  Human Mig chemokine: biochemical and functional characterization , 1995, The Journal of experimental medicine.

[55]  Eero Pukkala,et al.  Cancer risk after renal transplantation in the nordic countries, 1964–1986 , 1995, International journal of cancer.

[56]  B. Griffith,et al.  Solid tumors after heart transplantation: lethality of lung cancer. , 1995, The Annals of thoracic surgery.

[57]  I. Penn,et al.  Sarcomas in organ allograft recipients. , 1995, Transplantation.

[58]  G. Trinchieri Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. , 1995, Annual review of immunology.

[59]  M. Mihm,et al.  Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[60]  I. Svane,et al.  Methylcholanthrene‐induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression , 1996, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[61]  R. Zinkernagel,et al.  Decreased tumor surveillance in perforin-deficient mice , 1996, The Journal of experimental medicine.

[62]  Natale Cascinelli,et al.  Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma , 1996, Cancer.

[63]  I. Penn Malignant melanoma in organ allograft recipients. , 1996, Transplantation.

[64]  H. Ljunggren,et al.  Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice , 1996, European journal of immunology.

[65]  A. Angiolillo,et al.  Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. , 1996, Blood.

[66]  L. Old,et al.  Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[67]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[68]  J. Darnell,et al.  Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[69]  I. Svane,et al.  MCA Sarcomas Induced in scid Mice are More Immunogenic than MCA Sarcomas Induced in Congenic, Immunocompetent Mice , 1997, Scandinavian journal of immunology.

[70]  Aseem Kumar,et al.  Defective TNF-α-Induced Apoptosis in STAT1-Null Cells Due to Low Constitutive Levels of Caspases , 1997 .

[71]  S. Pestka,et al.  Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. , 1998, Immunity.

[72]  D. Scadden AIDS-related malignancies. , 1998, Current opinion in oncology.

[73]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[74]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[75]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[76]  James G. Boyd,et al.  Interferon–inducible T Cell Alpha Chemoattractant (I-TAC): A Novel Non-ELR CXC Chemokine with Potent Activity on Activated T Cells through Selective High Affinity Binding to CXCR3 , 1998, The Journal of experimental medicine.

[77]  S. Jackson,et al.  DNA double-strand break repair , 1999, Current Biology.

[78]  A. Hayday [gamma][delta] cells: a right time and a right place for a conserved third way of protection. , 2000, Annual review of immunology.

[79]  J. Trapani,et al.  Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells , 2000, The Journal of experimental medicine.

[80]  T. Blankenstein,et al.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. , 2000, Immunity.

[81]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[82]  T. Mcclanahan,et al.  Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. , 2000, Immunity.

[83]  J. Trapani,et al.  Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma , 2000, The Journal of experimental medicine.

[84]  M. Smyth,et al.  Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. , 2001, Blood.

[85]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[86]  J. Trapani,et al.  A fresh look at tumor immunosurveillance and immunotherapy , 2001, Nature Immunology.

[87]  A. Diefenbach,et al.  Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity , 2001, Nature.

[88]  A. Hayday,et al.  Regulation of Cutaneous Malignancy by γδ T Cells , 2001, Science.

[89]  M. Smyth,et al.  NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. , 2001, International immunology.

[90]  Drew M. Pardoll,et al.  Vaccines: Spinning molecular immunology into successful immunotherapy , 2002, Nature Reviews Immunology.

[91]  J. Trapani,et al.  Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ , 2002, The Journal of experimental medicine.

[92]  Diego Piccioli,et al.  Contact-dependent Stimulation and Inhibition of Dendritic Cells by Natural Killer Cells , 2002, The Journal of experimental medicine.

[93]  G. Trinchieri,et al.  Reciprocal Activating Interaction between Natural Killer Cells and Dendritic Cells , 2002, The Journal of experimental medicine.

[94]  Giovanni Melioli,et al.  Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells , 2002, The Journal of experimental medicine.

[95]  Lloyd J. Old,et al.  The roles of IFNγ in protection against tumor development and cancer immunoediting , 2002 .

[96]  M. Smyth,et al.  Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development , 2002, The Journal of experimental medicine.

[97]  B. A. D. Luster BIOCHEMICAL CHARACTERIZATION OF A y INTERFERON-INDUCIBLE CYTOKINE (IP-10) , 2003 .

[98]  I. Penn Posttransplant malignancies , 2004, World Journal of Urology.

[99]  A. Wilde,et al.  Now You See It, Now You Don't , 2004, Science's STKE.